We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Woodcock Defends Agency’s Accelerated Aduhelm Approval in Senate Hearing
Woodcock Defends Agency’s Accelerated Aduhelm Approval in Senate Hearing
Acting FDA Commissioner Janet Woodcock told members of the Senate Committee on Health, Education, Labor and Pensions yesterday that the FDA was simply doing what the Congress had instructed when it granted an accelerated approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab).